*, Harsha Prasada L (2015) Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia. Indian Pediatrics, 52. pp. 613-615. ISSN 0019-6061
![]() |
PDF
613.pdf - Published Version Restricted to Repository staff only Download (53kB) | Request a copy |
Abstract
Background: Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function. Sevelamer, an oral phosphate-binder is used in the treatment of hyperphosphatemia in children and adults on hemodialysis. Case characteristics: Two children with T-cell acute lymphoblastic leukemia who presented with a high tumour load and developed tumour lysis syndrome. Observation: Both children received Rasburicase and Sevelamer hydrochloride. The serum phosphate reduced to normal levels within 24-48 hrs of initiation of sevelamer hydrochloride. Message: Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Acute lymphoblastic leukemia, Hyperphosphatemia, Sevelamer hydrochloride, Tumour lysis syndrome |
Subjects: | Medicine > KMC Mangalore > Paediatrics |
Depositing User: | KMCMLR User |
Date Deposited: | 22 Aug 2016 12:09 |
Last Modified: | 22 Aug 2016 12:09 |
URI: | http://eprints.manipal.edu/id/eprint/146829 |
Actions (login required)
![]() |
View Item |